scispace - formally typeset
S

Stephen E. Weis

Researcher at University of North Texas Health Science Center

Publications -  95
Citations -  15875

Stephen E. Weis is an academic researcher from University of North Texas Health Science Center. The author has contributed to research in topics: Tuberculosis & Population. The author has an hindex of 38, co-authored 81 publications receiving 15299 citations. Previous affiliations of Stephen E. Weis include University of North Texas & Texas Department of State Health Services.

Papers
More filters
Journal ArticleDOI

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS

TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
Journal ArticleDOI

Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

Daniel D Murray, +1489 more
- 14 Oct 2015 - 
TL;DR: No associations with mortality were found with any circulating miRNAs studied and these results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection.
Journal ArticleDOI

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

TL;DR: As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-de...
Journal ArticleDOI

Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

TL;DR: People with average TC and LDL-C levels and below-average HDL-C may obtain significant clinical benefit from primary-prevention lipid modification, and on-treatment apoB, especially when combined with apoAI to form the apOB/AI ratio, may be a more accurate predictor than LDL- C of risk for first AMCE.